RE
Replimune Group, Inc.
REPL · NASDAQ
$12.92 -3.08% (-$0.41)
1M -13.69%
Market Cap $1.11B
P/E Ratio -
Div. Yield -
ROE 159.33%
Bulios Fair Price
$8.57
33.7% downside
Current Price
$12.92
Undervalued Fair Value Overvalued
According to Bulios Fair Price, REPL is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
0 /100
Expensive P/B 10.53x
EV/FFO N/A
P/E N/A
Growth
0 /100
Declining Book val. growth 33.11%
FCF growth N/A
EPS growth N/A
Profitability
-
N/A Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
0 /100
Poor ROA 117.65%
ROIC 136.14%
Asset turnover 0.00x
Debt
69 /100
Low Int. coverage -30.82x
Debt/Equity 0.26x
Current ratio 5.23x
Stability
78 /100
Stable Profitable years 0
Beta 0.94x
EPS volatility 8.40%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about REPL
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Sushil Patel
Employees
465
Headquarters
Woburn
Upcoming events
05 NOV
Earnings
Upcoming earnings report